Peripheral blood stem cell transplants have been associated with better response rates than conventional chemotherapy in patients with primary systemic amyloidosis. A higher incidence of gastrointestinal (GI) tract bleeding has been observed among amyloidosis patients undergoing peripheral stem cell transplantation. We retrospectively reviewed the medical records of such patients to identify those who had GI tract bleeding in the post-transplant period. Forty-five patients were studied. Nine patients had GI tract bleeding in the posttransplant period. The median post-transplant duration to onset of bleeding was 9.5 days (range 1 to 48 days). Three patients had lower GI tract bleeding, two had upper GI tract bleeding, and four had both. Diffuse esophagitis and gastritis were the most common findings on endoscopy. There were no correlations among the age, platelet nadir, or CD34 count of the graft and the risk of bleeding. Women were more likely to have GI tract bleeding (P = 0.015), as were patients with slow platelet engraftment (P = 0.02). Patients with multiorgan involvement and those on hemodialysis appeared to be at a higher risk of GI tract bleeding. The mean posttransplant hospital stay for those with GI tract bleeding was 37 days compared with 14.5 days for those who did not have GI tract bleeding (P = 0.0047). Bone Marrow Transplantation (2001) 28, 381-385. Keywords: GI bleeding; high-dose chemotherapy; stem cell transplantation; systemic amyloidosis Primary systemic amyloidosis is a rare plasma cell proliferative disorder with an incidence of nearly eight per million per year. The prognosis for patients diagnosed with the disorder remains poor, with a median survival of only 13 months for those seen within 1 month of diagnosis.
chemotherapy with melphalan and prednisone. [2] [3] [4] Addition of other drugs, namely vincristine, BCNU, and cyclophosphamide to melphalan and prednisone (VBMCP), has not improved the results over melphalan and prednisone alone. 5 Isolated reports of allogeneic bone marrow transplant have demonstrated benefit in amyloidosis. 6, 7 High-dose chemotherapy with autologous stem cell rescue is increasingly being used by several centers in the treatment of amyloidosis, and this has led to clinically important responses. [8] [9] [10] Gastrointestinal (GI) tract involvement is a common feature in systemic amyloidosis, but is often overlooked because of symptomatic involvement of other organs like the heart and kidneys. Autopsy studies show deposition of amyloid in the GI tract in 70% to 100% of patients. 11, 12 GI tract amyloidosis usually takes the form of malabsorption syndromes and nonspecific GI tract symptoms, 1, 13, 14 but GI tract bleeding as a manifestation has been reported by several authors. 11, [15] [16] [17] The structural involvement of the GI tract is often compounded by coagulation abnormalities secondary to factor deficiencies, 18 leading to episodes of GI tract bleeding. We have noticed a high incidence of GI tract bleeding among patients at our institution undergoing stem cell transplantation for systemic amyloidosis. We undertook a review of patients in whom GI tract bleeding developed post transplantation to identify risk factors for the development of bleeding.
Materials and methods
We retrospectively reviewed the medical records of patients who underwent high-dose chemotherapy with stem cell transplantation at our institution for primary systemic amyloidosis. Forty-five patients with biopsy-proven amyloidosis underwent transplantation between 1995 and April 2000 as part of an ongoing clinical trial. The patient characteristics are shown in Table 1 . Patients with familial, secondary, or localized amyloidosis and those with primary amyloidosis with only carpal tunnel syndrome or purpura were not candidates for transplantation. Patients had to have satisfactory cardiac (ejection fraction Ͼ50%) and pulmonary (forced expiratory volume in 1 s Ͼ45%, forced vital capacity Ͼ60%, diffusing capacity of the lung for carbon monoxide Ͼ50%) function to be considered for transplantation. Two different protocols were used for stem cell mobilization. Patients in one study received G-CSF (10 g/kg subcutaneously) daily, with stem cell collection beginning on day 5. The collection continued until the minimum target CD34 count of 2 × 10 6 cells/kg was achieved. Patients entered in the other study had stem cell mobilization with a combination of cyclophosphamide and growth factors. They received cyclophosphamide (1.5 g/m 2 ) on 2 consecutive days and then were started on GM-CSF (5 g/kg) from day 3. Stem cell collection was started once the WBC count exceeded 0.5 × 10 
Supportive care
Patients were managed predominantly on an outpatient basis. Fevers, inability to maintain adequate nutrition, or other complications prompted admission to the hospital. Hospitalized patients were treated in private rooms with high-efficiency particulate air filters. Standard neutropenic precautions were observed for all patients. Neutropenic fever prompted institution of a third-generation cephalosporin, with addition of vancomycin and amphotericin B sequentially over the next 48 to 72 h, as dictated by the response to initial therapy. Antibiotic therapy was further tailored to the results of blood cultures when positive. Red blood cell and platelet transfusions were given to maintain a Hb concentration of Ͼ8 g/dl and a platelet count of at least 20 000/l, respectively.
Statistical analyses
Statistical analyses were performed using Statview software from SAS Institute. A 2 test was used to compare nominal variables and a t-test for comparison of continuous variables.
Results
Forty-five patients (26 females and 19 males) underwent high-dose chemotherapy with stem cell rescue. Thirty-four were alive at the time of analysis, with a median followup of 7 months (range 0-47). Eleven patients died of various causes at a median of 2 months (range 0-22) after transplantation. Nine patients (20%) (seven females and two males) had GI tract bleeding in the post-transplantation period ( Table 2 ). The median post-transplantation duration to onset of bleeding was 9.5 days (range 1 to 48 days). The median platelet count and prothrombin time at the onset of bleeding were 22 000/l (11 000 to 280 000 l) and 10 s (9 to 19 s), respectively. Three patients had lower GI tract bleeding, two had upper GI tract bleeding, and four had upper and lower GI tract bleeding. Eight of the nine patients in whom GI tract bleeding developed had to be monitored in the intensive care unit because of the bleeding. Five patients underwent upper endoscopy; all demonstrated a diffusely inflamed friable esophageal and gastric mucosa. Additionally, one patient had a duodenal ulcer, and a discrete bleeding point was seen in another patient. Two patients had a colonoscopy, which demonstrated only internal hemorrhoids and no other obvious source of bleeding. Four of the nine patients in whom GI tract bleeding developed died in the post-transplantation period: three of multiorgan failure and one of pulmonary embolism. In only one patient was GI tract bleeding directly responsible for death.
We evaluated different pretransplantation variables and transplant-related variables to identify any predictive features (Table 3 ). There were no correlations among age, platelet nadir, and CD34 count of the graft or time to neutrophil engraftment and the risk of bleeding. Women were more likely to have GI tract bleeding (P = 0.015), as were patients with slow platelet engraftment (P = 0.02). Patients with multiorgan involvement (P = 0.076) and those on hemodialysis (P = 0.09) appeared to be at a higher risk for the development of GI tract bleeding. The median posttransplant hospital stay for those with GI tract bleeding was 37 days compared with 14.5 days for those who did not have GI tract bleeding (P = 0.002). The median number of red cell transfusions during the first 100 days post transplantation was significantly higher among those with GI bleeding (20 vs 4, P Ͻ 0.0001).
Discussion
GI tract involvement in systemic amyloidosis can manifest as various symptoms. 19 Most symptoms are nonspecific in the form of anorexia, nausea, vomiting, diarrhea, abdominal pain, and weight loss. Malabsorption syndrome is the most widely recognized feature of intestinal involvement in systemic amyloidosis. Patients who have amyloidosis can present less commonly with obstruction, infarction and per- LGI = lower gastrointestinal tract; N/A = did not reach Ͼ20; PT = prothrombin time; UGI = upper gastrointestinal tract.
Table 3
Results foration of the gut. However, GI tract bleeding, both from the upper and lower GI tract, has been reported by several authors. 11, 15, [20] [21] [22] [23] [24] [25] A high incidence of GI tract bleeding as a presenting symptom (25%-45%) of amyloidosis has been described by some authors. 15, 26 Levy et al 15 in a review from 1982 described 31 cases of GI tract bleeding associated with amyloidosis reported between 1948 and 1978. GI tract bleeding in amyloidosis can range from occult blood loss to exsanguinating hemorrhage. Endoscopic examination of the GI tract more often reveals diffuse involvement of the GI tract, rather than discrete lesions. Bleeding from isolated areas of amyloid deposition in the GI tract has been reported. Levy et al 15 noted diffuse involvement in more than half of the patients.
Characteristic
The mechanism of GI tract bleeding in amyloidosis is not clear but is probably multifactorial. Amyloid involvement of the gut can either be localized as nodules or the GI tract can be involved diffusely from the tongue to the anal orifice. 27, 28 Amyloidosis can involve the submucosa, muscularis mucosa, and subserosa, as well as the vasculaBone Marrow Transplantation ture of the bowel. 28, 29 Bleeding can arise from an ulcer in an area of localized amyloid deposition 16 or there might be diffuse oozing from the GI tract. Vascular deposition of amyloid can potentially make the vessels friable and may explain the diffuse oozing commonly seen. 27, 30 Amyloidosis can also involve the larger vessels supplying the bowel, leading to vascular obstruction and resultant infarction and perforation of the bowel. 22, 29 Hepatic involvement has been known to lead to portal hypertension with resultant variceal hemorrhage. 26 In addition to the structural abnormalities, there is a high prevalence of coagulation defects in patients with amyloidosis, which would contribute to the risk of bleeding. The commonly described findings include deficiencies of factor X, [31] [32] [33] antithrombin III, 34, 35 factor IX, 36 and inhibitors of the thrombin time. 18 GI tract complications are common after blood and marrow transplantation and are often a manifestation of acute and chronic GVHD or opportunistic viral and fungal infections of the GI tract. GI tract bleeding is a less recognized complication observed post transplantation, with an incidence of 5% to 15%. [37] [38] [39] [40] [41] Kaur et al 37 in their review of 579 patients undergoing BMT at one institution noted 50 patients (8.6%) with occult and 43 patients (7.4%) with overt GI tract bleeding. Autologous transplants accounted for the majority of bleeding episodes (33 of 43) in this series. The bleeding usually occurred during the second week post transplantation, at the same time as thrombocytopenia. Slightly more than half of the patients presented with hematemesis (24 of 43) and the rest with hematochezia or melena. Upper GI tract endoscopy most often revealed diffuse esophagitis and gastritis, with only five patients demonstrating discrete ulcers. Colonoscopy was not diagnostic. In only one patient was death directly attributable to bleeding. The authors were not able to identify any predisposing features in these patients.
In another large series of 1402 patients undergoing BMT, the incidence of moderate to severe GI tract bleeding was 14% during the first 100 days. 41 In that study, bleeding was observed more frequently after allogeneic transplants than autologous transplants and may have been related to GVHD-related bleeding and bleeding due to infections. A decrease in survival was noted for those patients in whom bleeding developed, although only one death was directly related to bleeding. In this setting, bleeding probably is a surrogate marker for the extent of conditioning regimenrelated tissue damage and other major transplant-related complications. Other studies have also demonstrated an association between poorer survival and incidence of GI tract bleeding in transplant patients. 42 GI tract bleeding occurring as a complication of autologous transplantation has been reported in the setting of amyloidosis. 8, [43] [44] [45] Comenzo et al 8 reported a 22% incidence (five of 23) of GI tract bleeding after high-dose melphalan and stem cell rescue for amyloidosis. In only one patient was the bleeding associated with delayed platelet engraftment. The same authors reported a 7% incidence of GI tract bleeding among 30 patients who underwent therapy with intermediate-dose melphalan and stem cell support. 45 In our group of patients, females appeared to be at higher risk for developing GI tract bleeding, but no such sex difference has been reported before and the reason for this difference is not clear. We did not find any relationship between any pretransplantation characteristic and increased risk of bleeding. Patients who had delayed platelet engraftment were at a higher risk for bleeding; however, no correlation was found between the platelet nadir and the development of bleeding. Patients with multiorgan amyloidosis tended to have a higher incidence of GI tract bleeding, as did those requiring hemodialysis. Multiorgan involvement, especially cardiac involvement, has been associated with a higher post-transplantation complication rate and mortality. 8 Upper GI tract endoscopy revealed diffuse esophagitis and gastritis in most of the patients, similar to that reported with GI tract bleeding in the setting of BMT. 37 The utility of esophagogastroduodenoscopy in this setting has been questioned, 37 given the diffuse involvement usually seen; however, in two of our patients discrete areas of bleeding were found and such areas can be treated by local measures.
The increased risk of GI tract bleeding during the posttransplantation period among patients with amyloidosis is not entirely understood. The tissue toxicity associated with the conditioning regimen often leads to loss of mucosal integrity post transplantation, and in those undergoing BMT for amyloidosis this is probably further aggravated by the underlying vascular rigidity and fragility. Abnormalities involving the coagulation cascade have been demonstrated in amyloidosis, but do not seem to have played any role in our patients. None of the patients in whom bleeding developed had abnormal results of coagulation studies before transplantation. Development of GI tract bleeding contributes significantly to the morbidity in these patients. Intensive care unit stay and invasive procedures add substantially to the cost of transplants in these patients. In our group of patients, the hospital stay was more than doubled among those in whom bleeding developed. No difference was found in another study, 37 but this discrepancy could be related to the predominantly outpatient nature of our autologous transplant program.
In conclusion, GI tract bleeding occurs more often after autologous stem cell transplantation for amyloidosis than for other disorders. It leads to increased hospital and intensive care unit stay, more invasive procedures, and increased morbidity associated with the transplant. No correctable factors could be found in our study that increased the risk of bleeding. Patients who have GI tract bleeding post transplantation may benefit from endoscopic procedures if discrete areas of bleeding are found. Coagulation tests may help uncover abnormalities. Prophylactic use of proton pump inhibitors or H 2 blockers and maintenance of platelet counts above 50 000/l may be of benefit and should be evaluated in a prospective fashion.
